The health-economic implications of the "Irbesartan in Diabetic Nephropathy Trial" (IDNT) in France and Belgium

被引：1
|
作者：
Palmer, AJ
Annemans, L
Roze, S
Lamotte, M
Guilhaume, C
Gabriel, S
Carita, P
Chen, R
Simon, T
Rodby, R
Cordonnier, DJ
机构：
[1] CHU Grenoble, F-38043 Grenoble, France
[2] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Sanofi Synthelabo, Bagneux, France
[5] State Univ Ghent, HEDM, Meise, Belgium
[6] CORE Ctr Outcomes Res, Basel, Switzerland
来源：
VALUE IN HEALTH | 2002年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61441-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：546 / 546
页数：1
相关论文
共 50 条
  • [1] An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting
    Palmer, AJ
    Annemans, L
    Roze, S
    Lamotte, M
    Rodby, RA
    Bilous, RW
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (10) : 733 - 738
  • [2] An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting
    A J Palmer
    L Annemans
    S Roze
    M Lamotte
    R A Rodby
    R W Bilous
    [J]. Journal of Human Hypertension, 2004, 18 : 733 - 738
  • [3] Irbesartan is projected to save money while prolonging life in Type II diabetic nephropathy: A pharmacoeconomic model of the irbesartan in diabetic nephropathy trial (IDNT).
    Rodby, R
    Chen, R
    Simon, T
    Sengupta, N
    Borenstein, J
    Chiou, C
    Smitten, A
    Palmer, A
    Annemans, L
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 687A - 687A
  • [4] An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings
    Palmer, AJ
    Annemans, L
    Roze, S
    Lamotte, M
    Rodby, RA
    Cordonnier, DJ
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) : 2059 - 2066
  • [5] Clinical Trial Design Based on Disease Progression and Pharmacological Effects in the Irbesartan Diabetic Nephropathy Trial (IDNT)
    Chan, Phyllis
    Chen, Chunlin
    Clawson, David
    Soares, Holly
    Pupim, Lara
    LaCreta, Frank
    AbuTarif, Malaz
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S113 - S113
  • [6] Cardiovascular outcomes in the irbesartan diabetic nephropathy trial (IDNT) of patients with type 2 diabetes and overt nephropathy.
    Berl, T
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 651A - 651A
  • [7] COMPLICATIONS OF CHRONIC KIDNEY DISEASE (CKD) BY LEVEL OF ALBUMINURIA AND PROTEINURIA IN THE IRBESARTAN IN DIABETIC NEPHROPATHY TRIAL (IDNT)
    Viswanathan, Gautham
    Tighiouart, Hocine
    Muntner, Paul
    Lewis, Julia
    Sarnak, Mark
    Stevens, Lesley
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) : A102 - A102
  • [8] Effect of baseline proteinuria and change in proteinuria with treatment on the risk of renal endpoints in the irbesartan diabetic nephropathy trial (IDNT).
    Atkins, RC
    Briganti, EM
    Wiegmann, TB
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 7A - 7A
  • [9] Health-economic consequences of diabetic foot lesions
    Tennvall, GR
    Apelqvist, J
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 : S132 - S139
  • [10] Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial
    Hunsicker, LG
    Atkins, RC
    Lewis, JB
    Braden, G
    De Crespigny, PJC
    DeFerrari, G
    Drury, P
    Locatelli, F
    Wiegmann, TB
    Lewis, EJ
    [J]. KIDNEY INTERNATIONAL, 2004, 66 : S99 - S101
12345